Polyrizon Ltd
Polyrizon Ltd is a biotechnology company focused on pharmaceuticals and medical research, generating revenue primarily through the development and commercialization of innovative therapies.
Business. Polyrizon Ltd (PLRZ.O) is a biotechnology and medical research company headquartered in the United States. The firm operates within the pharmaceuticals and medical research industry, focusing on product-based revenue models. Polyrizon is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
At a glance
What drives this business
The watch-list the newsroom runs for this company — derived from its sector path, sharpened layer by layer. Not investment advice.
News & coverage
0Sector rotation
Developing storylines
Analysis
AI analysisOpportunity
Upcoming catalysts
Scheduled public events. Informational only — not investment advice.
- Company
- EarningsQ3 2026 earnings (expected)2026-10-28 · estimated
- Macro
- Rate decisionBank of England rate decision (press conf.)2026-08-06 · GB
- Rate decisionReserve Bank of Australia rate decision (press conf.)2026-08-12 · AU
- Rate decisionNorges Bank rate decision (press conf.)2026-08-20 · NO
- Rate decisionSveriges Riksbank rate decision (press conf.)2026-09-03 · SE
- Rate decisionBank of Canada rate decision (press conf.)2026-09-09 · CA
- Rate decisionEuropean Central Bank rate decision (press conf.)2026-09-10 · EU
- Macro & political
- ElectionSE Swedish Election2026-09-14 · SE
- ElectionUS U.S. Midterms2026-11-03 · US
- ElectionFR French Legislative2027-06-01 · FR
Pre-earnings brief
Signals & dispatch
Composite-score breakdown
Synthesis
Polyrizon Ltd (PLRZ.O) is a biotechnology and medical research company headquartered in the United States. The firm operates within the pharmaceuticals and medical research industry, focusing on product-based revenue models. Polyrizon is primarily listed on the NASDAQ stock exchange. Specific details regarding operating segments and geographic revenue mix are not available.
Polyrizon maintains a strong liquidity position, with a current ratio of 29.03, indicating a significant buffer of current assets over current liabilities. The company's cash and equivalents amount to $1.3 million, and it has no long-term debt, contributing to a debt-to-equity ratio of 0.0. The price-to-book ratio of 1.34 suggests that the market values the company slightly above its book value, while the price-to-tangible-book ratio is identical, indicating no intangible asset premium.
The company's profitability metrics are negative, with a return on equity of -15.89% and a return on assets of -15.56%, reflecting a loss-making position. The operating income and net income are -$6.25 million and -$3.34 million, respectively, indicating a challenging financial performance. The EV/EBITDA ratio of -4.29 further underscores the company's unprofitability and the market's cautious valuation.
Polyrizon's revenue concentration and geographic exposure are not explicitly detailed in the available data, but the absence of disclosed segments suggests a potentially undiversified business model. The company's operations are likely concentrated in a single therapeutic area or geographic region, which could pose concentration risks.
The company's growth trajectory is uncertain, with no specific revenue growth projections provided in the outlook. The operating cash flow of -$4.53 million and free cash flow of -$3.0 million indicate a cash outflow, which could constrain future growth initiatives. The capital expenditure of -$7,000 is minimal, suggesting limited investment in expansion or new projects.
Risk factors for Polyrizon include the potential for dilution, although the risk is currently assessed as low. The company has no immediate filing-based liquidity or dilution flags, and the valuation adjustments do not indicate significant dilution pressures. However, the negative profitability metrics and cash outflows highlight operational risks that could affect long-term stability.
Recent events and filings do not show any significant developments that would impact the company's financial position or strategic direction. The absence of recent major events suggests a stable but stagnant operational environment.
- Polyrizon has a strong liquidity position with a current ratio of 29.03 and no long-term debt.
- The company is currently unprofitable, with a return on equity of -15.89% and a return on assets of -15.56%.
- The EV/EBITDA ratio of -4.29 reflects the market's cautious valuation of the company's unprofitable operations.
- The company's revenue concentration and geographic exposure are not explicitly detailed, suggesting potential diversification risks.
- The absence of immediate liquidity or dilution flags indicates a low near-term risk of capital structure changes.
Bull / Bear case
Generated · model-assistedIn focus — financials by report
Valuation
Revenue by segment
Business relationships
Supply chain
Peer comparison
Market position
Stress test
Predictor forecast
Options
Short squeeze
Earnings-call key lines
Estimate revisions
consensus EPS · 26-week trendSell-side observations
Themes
ESG
Risk factors
- No immediate filing-based liquidity or dilution flags were detected.
Benchmarks vs cohort
Corporate actions / M&A
FX exposure
Comparable transactions
Derivatives & instruments
Actions
Ask Handelsavisen
- Market data
- Market data cache
- Issuer disclosures
- Public news
- Earnings transcripts
- Consensus estimates
- ESG data
- Return On Equitynet_income / total_equity
- Price To Bookmarket_price / (adjusted_book_value / shares_outstanding_diluted)
- Dilution Ratio(shares_outstanding_diluted - shares_outstanding_basic) / shares_outstanding_basic
- Market Priceinput from market-data provider (delayed close or quote-shim mid)
- Market Capmarket_price * shares_outstanding_diluted
- Net Cashcash_and_equivalents + short_term_investments - short_term_debt - long_term_debt
- Polyrizon Ltd Market data — financials · 2026-05-29
Ownership & reference
Insider activity
- Director, Chief Executive Officer · Ordinary SharesSold 500 @ $11,85$6K · 2026-03-31
- Director · Ordinary SharesSold 942 @ $12,36$12K · 2026-03-31
- Director · Ordinary SharesSold 3 292 @ $12,05$40K · 2026-03-31
- Director · Ordinary SharesSold 100 @ $11,00$1K · 2026-03-30
- Director, Chief Executive Officer · Ordinary SharesSold 3 900 @ $10,90$43K · 2026-03-30
- Director, Chief Technology Officer · Ordinary SharesSold 2 917 @ $10,90$32K · 2026-03-30
Short positioning
Geographic breakdown
Intel & risk
Evidence & claims
From filings & derived data- Return on equity (FY 2025-12-31): -15.9%Derived (calculated)
- Return on assets (FY 2025-12-31): -15.6%Derived (calculated)
- Current ratio (FY 2025-12-31): 29.03xDerived (calculated)
- R&D expense (YoY) (2025-12-31 vs 2024-12-31): 299.4%Derived (calculated)
- Operating income (YoY) (2025-12-31 vs 2024-12-31): -380.0%Derived (calculated)
- Operating cash flow (YoY) (2025-12-31 vs 2024-12-31): -294.8%Derived (calculated)
- EPS (basic) (YoY) (2025-12-31 vs 2024-12-31): -99.4%Derived (calculated)
- Net income (YoY) (2025-12-31 vs 2024-12-31): -115.9%Derived (calculated)
- Capex (YoY) (2025-12-31 vs 2022-12-31): 133.3%Derived (calculated)
- EPS (diluted) (YoY) (2025-12-31 vs 2024-12-31): -99.4%Derived (calculated)
- Total assets (YoY) (2025-12-31 vs 2024-12-31): 286.5%Derived (calculated)
- Cash & equivalents (YoY) (2025-12-31 vs 2024-12-31): -48.9%Derived (calculated)
- Shareholders' equity (YoY) (2025-12-31 vs 2024-12-31): 297.2%Derived (calculated)
- Capex (annual): USD 7KSEC XBRL filing
- Current liabilities (annual): USD 443KSEC XBRL filing
- Cash & equivalents (annual): USD 1.31MSEC XBRL filing
- Total assets (annual): USD 21.44MSEC XBRL filing
- Operating cash flow (annual): USD -4.53MSEC XBRL filing
- Net income (annual): USD -3.33MSEC XBRL filing
- Shares outstanding (annual): 1.61MSEC XBRL filing
- Shareholders' equity (annual): USD 20.99MSEC XBRL filing
- Current assets (annual): USD 12.86MSEC XBRL filing
- EPS (basic) (annual): USD-PER-SHARES 5SEC XBRL filing
- R&D expense (annual): USD 2.13MSEC XBRL filing